Shots: FDA approves Kyowa Kirin’s Poteligeo drug for R/R Mycosis fungoides (MF) and Sézary syndrome (SS) Poteligeo received Orphan Drug designation with addition permission granted on basis of Priority Review and Breakthrough Therapy The approval is based on a clinical trial of 372 patients with MF or SS. Study reported mPFS (Poteligeo vs Vorinostat) is […]Read More
